[1]吴兴树,苏智祥.小青龙汤加减联合西医常规对哮喘伴慢性阻塞性肺疾病支气管痉挛患者的治疗作用[J].西部中医药,2022,35(09):111-114.[doi:10.12174/j.issn.2096-9600.2022.09.22]
　WU Xingshu,SU Zhixiang.Clinical Effects of Modified Xiaoqinglong Tang and Conventional Western Medicine in Treating Bronchospasm in Patients with ACOS[J].Western Journal of Traditional Chinese Medicine,2022,35(09):111-114.[doi:10.12174/j.issn.2096-9600.2022.09.22]
点击复制

小青龙汤加减联合西医常规对哮喘伴慢性阻塞性肺疾病支气管痉挛患者的治疗作用
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年09期
页码:
111-114
栏目:
衷中参西
出版日期:
2022-09-15

文章信息/Info

Title:
Clinical Effects of Modified Xiaoqinglong Tang and Conventional Western Medicine in Treating Bronchospasm in Patients with ACOS
作者:
吴兴树1, 苏智祥2
1.陕西省人民医院，陕西 西安 710068
2.陕西省肿瘤医院
Author(s):
WU Xingshu1, SU Zhixiang2
1.Shaanxi Provincial People's Hospital, Xi'an 710068, China
2.Shaanxi Provincial Cancer Hospital
关键词:
慢性阻塞性肺疾病; 支气管痉挛; 哮喘; 小青龙汤加减
Keywords:
COPD; bronchospasm; asthma; modified
分类号:
R256.14
DOI:
10.12174/j.issn.2096-9600.2022.09.22
摘要:
目的探讨小青龙汤加减对哮喘伴慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）患者支气管痉挛的治疗作用。 方法将哮喘伴COPD患者112例采取随机数字分配法分为对照组和研究组各56例，对照组予盐酸氨溴索片、氨茶碱片及吸入沙美特罗替卡松治疗；研究组在对照组治疗的基础上予小青龙汤加减治疗，每日1剂，分早晚2次口服，两组均治疗2个月。观察治疗前后两组患者肺功能、气道炎症反应、实验室相关指标、临床疗效及并发症发生情况。 结果研究组有效率为87.50%，高于对照组的71.43%（P＜0.05）。与治疗前比较，两组治疗后第一秒用力呼气量（forced expiratory volume in one second，FEV1）、最大肺活量（forced vital capacity，FVC）、第一秒用力呼气容积（first second forced expiratory volume，FEV1%）pre、第一秒用力肺活量/潮气量比值（first second forced vital capacity/tidal volume，FEV1/FVC）升高，血清转化生长因子β1（transforming growth factor-β1，TGF-β1）、白细胞介素6（interleukin-6，IL-6）、肿瘤坏死因子α（tumor necrosis factor α，TNF-α）及血清可溶性细胞间黏附分子1（soluble intercellular adhesion molecule-1，sICAM-1）、肺表面活性蛋白D（Lung surfactant protein D，SP-D）降低（P＜0.05）；治疗后研究组FEV1、FVC、FEV1%pre、FEV1/FVC较对照组升高，血清TGF-β1、IL-6、TNF-α及SP-D、sICAM-1较对照组降低（P＜0.05）。 结论在西医常规治疗的基础上予小青龙汤加减治疗能够改善哮喘伴COPD患者支气管痉挛，其疗效的提高与改善肺功能、降低气道炎症指标具有相关性。
Abstract:
ObjectiveTo discuss clinical effects of modified Xiaoqinglong Tang in the treatment of bronchospasm in patients with asthma-COPD overlap syndrome (ACOS). MethodsAll 112 patients were divdied into the control group and the study group by using random number allocation method, 56 cases in each group, the control group was treated by ambroxol hydrochloride tablets, aminophylline tablets and inhaled salmeterol fluticasone; and the study group by modified Xiaoqinglong Tang on the foundation of the therapy the control group accepted, one dose each day, taking it orally twice in the morning and evening, both groups were treated for two months. To observe lung function, airway inflammatory response, lab-related indexes, clinical effects and the incidence of the complications before and after treatment in two groups. ResultsThe effective rate of the study group was 87.50%, higher than 71.43% of the control group (P<0.05). Compared with before the treatment, FEV1, FVC, FEV1% pre and FEV1/FVC were raised in two groups after the treatment, the levels of TGF-β1, IL-6 and TNF-α, sICAM-1 and SP-D values were lowered (P<0.05); compared with the control group, FEV1, FVC, FEV1% pre and FEV1/FVC of the study group were improved after the treatment, the levels of TGF-β1, IL-6 and TNF-α, SP-D and sICAM-1 were lowered (P<0.05). ConclusionOn the foundation of routine therapy of Western medicine, modified Xiaoqinglong Tang could improve bronchospasm in patients with asthma and COPD, and its clinical improvements are related to improving lung function and lowering the indexes of airway inflammation.

相似文献/References:

[1]王萍.慢性阻塞性肺病患者实施临床护理路径的疗效分析[J].西部中医药,2014,27(11):140.
[2]王 燕,孙凤英,倪 军.慢性阻塞性肺疾病患者非药物治疗依从性与生活质量相关性的研究[J].西部中医药,2015,28(03):89.
[3]郭晓燕,尹广超,陆城华,等.川芎平喘合剂对COPD患者血管内皮功能的调节作用[J].西部中医药,2015,28(05):1.
[4]王振伟,杨佩兰,沈丽,等.百部养肺煎膏治疗COPD稳定期患者的临床研究[J].西部中医药,2015,28(05):56.
[5]赵宇冰,林丽明.老年慢性阻塞性肺疾病患者缓解期的社区康复治疗[J].西部中医药,2012,25(08):59.
　ZHAO Yu-bing,LIN Li-ming.Community Rehabilitation Therapy for Senile Patients with COPD at Remission Stage[J].Western Journal of Traditional Chinese Medicine,2012,25(09):59.
[6]张旭辉,杨虹.咳喘宁胶囊治疗稳定期慢性阻塞性肺疾病的疗效评价[J].西部中医药,2016,29(03):1.
　ZHANG Xuhui,YANG Hong.Evaluation of Clinical Effects of KeChuanNing Capsules in Treating Chronic Obstructive Pulmonary Disease at Stable Stage[J].Western Journal of Traditional Chinese Medicine,2016,29(09):1.
[7]晏燕,孙建勤,姜冰玉,等.中西医结合治疗老年慢性阻塞性肺疾病急性加重期的临床疗效[J].西部中医药,2016,29(07):96.
　YAN Yan,SUN Jianqin,JIANG Bingyu,et al.Clinical Effects of Integrative Medicine in Treating Chronic Obstructive Pulmonary Disease of Senile Patients at Acute Exacerbation[J].Western Journal of Traditional Chinese Medicine,2016,29(09):96.
[8]施巍,苟小军,王道才,等.刺络放血法治疗慢性阻塞性肺疾病急性加重期48例[J].西部中医药,2017,30(02):96.
　SHI Wei,GOU Xiaojun,WANG Daocai,et al.Blood-letting Therapy in Treating 48 Cases of Chronic Obstructive Pulmonary Disease at Acute Exacerbation Stage[J].Western Journal of Traditional Chinese Medicine,2017,30(09):96.
[9]郭晓燕,腾飞,张惠勇.川芎平喘合剂治疗慢性阻塞性肺疾病的随机对照研究[J].西部中医药,2018,31(01):1.
　GUO Xiaoyan,TENG Fei,ZHANG Huiyong.A Randomized, Controlled Study of ChuanXiong PingChuan Mixture in Treating Chronic Obstructive Pulmonary Disease[J].Western Journal of Traditional Chinese Medicine,2018,31(09):1.
[10]史素丽,尚秀娟△,曹凤英.老年慢性阻塞性肺疾病患者主观幸福度及影响因素分析[J].西部中医药,2016,29(01):93.
　SHI Suli,SHANG Xiujuan,CAO Fengying.Analysis of Influencing Factors and Subjective Happiness Index of Senile Patients with Chronic Obstructive Pulmonary Disease[J].Western Journal of Traditional Chinese Medicine,2016,29(09):93.

备注/Memo

备注/Memo:
吴兴树（1978—），男，主治医师。研究方向：哮喘-慢性阻塞性肺疾病的诊治。陕西省卫生健康委员会2019年科研课题（19PJ066）。
更新日期/Last Update: 2022-10-08